Previous 10 | Next 10 |
SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, th...
SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has co...
Gainers: Doximity (NYSE:DOCS) +20%. Aptevo Therapeutics (NASDAQ:APVO) +17%. Biofrontera (NASDAQ:BFRA) +14%. Karyopharm Therapeutics (NASDAQ:KPTI) +14%. Teva Pharmaceutical (NYSE:TEVA) +9%. Losers: Varex Imaging (NASDAQ:VREX) -11%. BioCardia (NASDAQ...
Gainers: Society Pass (NASDAQ:SOPA) +57%. Tritium DCFC Limited (NASDAQ:DCFC) +36%. Peloton Interactive (NASDAQ:PTON) +29%. IN8bio (NASDAQ:INAB) +22%. Teradata Corporation (NYSE:TDC) +24%. Atomera (NASDAQ:ATOM) +21%. BioCardia (NASDAQ:BCDA) +20%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +18%. ...
Gainers: BioCardia (NASDAQ:BCDA) +30%. Aptorum Group (NASDAQ:APM) +22%. Bon Natural Life (NASDAQ:BON) +17%. Lightning eMotors (NYSE:ZEV) +15%. Modine Manufacturing (NYSE:MOD) +14%. Battalion Oil (NYSE:BATL) +13%. DXC Technology (NYSE:DXC) +12%. Redwire (NYSE:RDW) +11%. T-Mobile US (NASDAQ:TMU...
Gainers: BioCardia BCDA +32%. Biophytis BPTS +17%. Mersana Therapeutics MRSN +7%. Liquidia (NASDAQ:LQDA) +5%. Vaccitech (NASDAQ:VACC) +3%. Losers: Kiromic BioPharma KRBP -17%. Mainz Biomed (NASDAQ:MYNZ) -9%. Vaccinex (NASDAQ:VCNX) -7%. NeuroBo Phar...
Buying Penny Stocks Today? Here’s What You Need to Know With another day of trading penny stocks and blue chips here, understanding what’s going on in the stock market is crucial. Now, every day with penny stocks is different and as a result, knowing what factors are i...
The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to BioCardia's (NASDAQ:BCDA) CardiAMP Cell Therapy System to treat heart failure. The company said it is believed to be the first cardiac cell therapy to receive the FDA's breakthrough device status. The ...
BioCardia (NASDAQ:BCDA) +32% receives FDA breakthrough device designation for CardiAMP cell therapy system for heart failure. Bon Natural Life (NASDAQ:BON) +29% on FY results. Lightning eMotors (NYSE:ZEV) +19% after electrification deal with General Motors. Redwire (NYSE:RDW) +...
SUNNYVALE, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentati...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therap...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...